Catalyst Wire Dossier Catalyst Wire Dossier

Allogeneic umbilical cord blood-derived CD19-specific T cells

· M.D. Anderson Cancer Center
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Allogeneic umbilical cord blood-derived CD19-specific T cells, covering 2017-08-03 to 2017-08-03. Get the full timeline:

Most recent: Clinical Trial Update: Infusion of Allogeneic Umbilical Cord Blood-Derived Cluster of Differentiation Antigen 19 (CD19)-Specific T Cells [Phase 1]

See pricing